STADA Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/15/2020)
| Balance Sheet | Total Assets | 5,247,300,000.00 | ROE | – |
| Balance Sheet | Total Equity | 1,158,487,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -244,412,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 361,362,000.00 | – | – |
| Cashflow | Operating Cash Flow | 444,080,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -1.57 | Div. Yield | – |
| Income | Net Income | 318,002,000.00 | P/E | – |
| Income | Shares Outstanding | 62,283,300.00 | P/B | – |
| Income | Total Revenue | 3,734,843,000.00 | P/S | – |
Ratios calculated on: –
Company Description
STADA Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company concentrates on the development and marketing of products with off-patent active pharmaceutical ingredients. The Company's primary business segments are: Generics, comprising low-priced and active-ingredient products, and Branded Products, focusing on multisource products that are accessible without active ingredient research. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities, as well as Group holdings/other segment. On March 27, 2012, the Company announced that it has founded a subsidiary based in Sydney, Australia, under the name STADA Pharmaceuticals Australia Pty Ltd
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.stada.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more